ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT07021989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investigate using circulating tumor DNA (ctDNA) at pre-determined time points using Foresight CLARITY LDT, an ultra-sensitive liquid biopsy platform that detects Minimal residual disease (MRD) in patients with B-cell lymphomas using the phased variant enrichment and sequencing technology (PhasEDq) to determine response to study interventions.
Study identification
- NCT ID
- NCT07021989
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 38 participants
Conditions and interventions
Interventions
- Pembrolizumab Drug
- Non-investigational, involved site radiotherapy (ISRT) Radiation
- Gemcitabine Drug
- Vinorelbine Drug
- Liposomal Doxorubicin Drug
- Foresight CLARITY™ LDT Device
- Pegfilgrastim Drug
- Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT) Procedure
Drug · Radiation · Device + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 17, 2026
- Primary completion
- Jul 30, 2029
- Completion
- Mar 30, 2034
- Last update posted
- Aug 19, 2026
2026 – 2034
United States locations
- U.S. sites
- 6
- U.S. states
- 1
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Davis | Davis | California | 95616 | Not yet recruiting |
| University of California San Francisco-Fresno | Fresno | California | 93701 | Not yet recruiting |
| University of California Irvine | Irvine | California | 92617 | Not yet recruiting |
| University of California, San Diego | La Jolla | California | 92093 | Not yet recruiting |
| Unversity of California, Los Angeles | Los Angeles | California | 90095 | Not yet recruiting |
| University of California, San Francisco | San Francisco | California | 94143 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07021989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07021989 live on ClinicalTrials.gov.